BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32390401)

  • 1. The Role of Resolvin D1 in the Differential Diagnosis of the Cholangiocarcinoma and Benign Biliary Diseases.
    Gül-Utku Ö; Karatay E; Ergül B; Kisa Ü; Erdin Z; Oğuz D
    Clin Lab; 2020 May; 66(5):. PubMed ID: 32390401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile-derived circulating extracellular miR-30d-5p and miR-92a-3p as potential biomarkers for cholangiocarcinoma.
    Han HS; Kim MJ; Han JH; Yun J; Kim HK; Yang Y; Kim KB; Park SM
    Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):41-50. PubMed ID: 31784323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
    Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
    BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP.
    Park MS; Kim TK; Kim KW; Park SW; Lee JK; Kim JS; Lee JH; Kim KA; Kim AY; Kim PN; Lee MG; Ha HK
    Radiology; 2004 Oct; 233(1):234-40. PubMed ID: 15333766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.
    Wasenang W; Chaiyarit P; Proungvitaya S; Limpaiboon T
    Clin Epigenetics; 2019 Mar; 11(1):39. PubMed ID: 30832707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cathepsin B to cystatin C ratio as a potential marker for the diagnosis of cholangiocarcinoma.
    Monsouvanh A; Proungvitaya T; Limpaiboon T; Wongkham C; Wongkham S; Luvira V; Proungvitaya S
    Asian Pac J Cancer Prev; 2014; 15(21):9511-5. PubMed ID: 25422248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls.
    Zhang X; Yang Z; Shi Z; Zhu Z; Li C; Du Z; Zhang Y; Wang Z; Jiao Z; Tian X; Zhang J; Zhai W; Kan Q
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105775. PubMed ID: 33130021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma.
    Tummanatsakun D; Proungvitaya T; Roytrakul S; Limpaiboon T; Wongkham S; Wongkham C; Silsirivanit A; Somintara O; Sangkhamanon S; Proungvitaya S
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31454981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total serum bile acid as a potential marker for the diagnosis of cholangiocarcinoma without jaundice.
    Sombattheera S; Proungvitaya T; Limpaiboon T; Wongkham S; Wongkham C; Luvira V; Proungvitaya S
    Asian Pac J Cancer Prev; 2015; 16(4):1367-70. PubMed ID: 25743800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristic Features of Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis.
    Ishii Y; Sasaki T; Serikawa M; Kobayashi K; Kamigaki M; Minami T; Okazaki A; Yukutake M; Ishigaki T; Kosaka K; Mouri T; Yoshimi S; Chayama K
    Hepatogastroenterology; 2014 May; 61(131):567-73. PubMed ID: 26176037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma.
    Tang Z; Yang Y; Wang X; Meng W; Li X
    BMJ Open; 2019 Jan; 9(1):e021693. PubMed ID: 30700476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.
    Chen WM; Wei KL; Chen YS; Chang PJ; Tung SY; Chang TS; Huang HC; Shen CH; Hsieh YY; Wu CS
    World J Surg Oncol; 2016 May; 14():140. PubMed ID: 27142076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience.
    Kuzu UB; Ödemiş B; Suna N; Yıldız H; Parlak E; Dişibeyaz S; Torun S; Akpınar MY; Coşkun O; Turhan N; Yüksel M; Kayaçetin E
    J Gastrointest Cancer; 2016 Mar; 47(1):8-14. PubMed ID: 26537791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
    Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
    Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study.
    Navaneethan U; Parsi MA; Lourdusamy V; Bhatt A; Gutierrez NG; Grove D; Sanaka MR; Hammel JP; Stevens T; Vargo JJ; Dweik RA
    Gastrointest Endosc; 2015 Apr; 81(4):943-9.e1. PubMed ID: 25500329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis.
    Alvaro D; Macarri G; Mancino MG; Marzioni M; Bragazzi M; Onori P; Corradini SG; Invernizzi P; Franchitto A; Attili AF; Gaudio E; Benedetti A
    Ann Intern Med; 2007 Oct; 147(7):451-9. PubMed ID: 17909206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.